Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (PBH) Stock Competitors & Peer Comparison
See (PBH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PBH | $46.75 | +1.79% | 2.2B | 11.94 | $3.91 | N/A |
| MCK | $760.57 | +1.79% | 91.5B | 19.81 | $38.41 | +0.42% |
| COR | $257.71 | -1.30% | 50.1B | 19.75 | $13.05 | +0.91% |
| CAH | $195.20 | +0.42% | 45.7B | 29.85 | $6.54 | +1.04% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $72.72 | +0.15% | 8.3B | 21.97 | $3.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $36.61 | +0.94% | 2.3B | 43.58 | $0.84 | N/A |
| ACH | $2.91 | -4.28% | 222.9M | -2.16 | -$1.35 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
Stock Comparison
PBH vs MCK Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, MCK has a market cap of 91.5B. Regarding current trading prices, PBH is priced at $46.75, while MCK trades at $760.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas MCK's P/E ratio is 19.81. In terms of profitability, PBH's ROE is +0.10%, compared to MCK's ROE of -2.65%. Regarding short-term risk, PBH is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check MCK's competition here
PBH vs COR Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, COR has a market cap of 50.1B. Regarding current trading prices, PBH is priced at $46.75, while COR trades at $257.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas COR's P/E ratio is 19.75. In terms of profitability, PBH's ROE is +0.10%, compared to COR's ROE of +1.16%. Regarding short-term risk, PBH is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check COR's competition here
PBH vs CAH Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, CAH has a market cap of 45.7B. Regarding current trading prices, PBH is priced at $46.75, while CAH trades at $195.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas CAH's P/E ratio is 29.85. In terms of profitability, PBH's ROE is +0.10%, compared to CAH's ROE of -0.56%. Regarding short-term risk, PBH is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check CAH's competition here
PBH vs ABC Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, PBH is priced at $46.75, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas ABC's P/E ratio is 21.92. In terms of profitability, PBH's ROE is +0.10%, compared to ABC's ROE of +1.16%. Regarding short-term risk, PBH is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check ABC's competition here
PBH vs HSIC Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, HSIC has a market cap of 8.3B. Regarding current trading prices, PBH is priced at $46.75, while HSIC trades at $72.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas HSIC's P/E ratio is 21.97. In terms of profitability, PBH's ROE is +0.10%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, PBH is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check HSIC's competition here
PBH vs PDCO Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, PBH is priced at $46.75, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas PDCO's P/E ratio is 20.48. In terms of profitability, PBH's ROE is +0.10%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, PBH is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check PDCO's competition here
PBH vs GRDN Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, GRDN has a market cap of 2.3B. Regarding current trading prices, PBH is priced at $46.75, while GRDN trades at $36.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas GRDN's P/E ratio is 43.58. In terms of profitability, PBH's ROE is +0.10%, compared to GRDN's ROE of +0.27%. Regarding short-term risk, PBH is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check GRDN's competition here
PBH vs ACH Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, ACH has a market cap of 222.9M. Regarding current trading prices, PBH is priced at $46.75, while ACH trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas ACH's P/E ratio is -2.16. In terms of profitability, PBH's ROE is +0.10%, compared to ACH's ROE of +2.65%. Regarding short-term risk, PBH is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check ACH's competition here
PBH vs OMI Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, PBH is priced at $46.75, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas OMI's P/E ratio is -0.47. In terms of profitability, PBH's ROE is +0.10%, compared to OMI's ROE of +2.69%. Regarding short-term risk, PBH is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check OMI's competition here
PBH vs GEG Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, GEG has a market cap of 67.7M. Regarding current trading prices, PBH is priced at $46.75, while GEG trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas GEG's P/E ratio is -2.70. In terms of profitability, PBH's ROE is +0.10%, compared to GEG's ROE of -0.38%. Regarding short-term risk, PBH is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check GEG's competition here
PBH vs HX Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, PBH is priced at $46.75, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas HX's P/E ratio is -1.84. In terms of profitability, PBH's ROE is +0.10%, compared to HX's ROE of -1.07%. Regarding short-term risk, PBH is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check HX's competition here
PBH vs WGRX Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, WGRX has a market cap of 6.1M. Regarding current trading prices, PBH is priced at $46.75, while WGRX trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas WGRX's P/E ratio is -0.06. In terms of profitability, PBH's ROE is +0.10%, compared to WGRX's ROE of +1417.60%. Regarding short-term risk, PBH is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check WGRX's competition here
PBH vs ZYXI Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, PBH is priced at $46.75, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, PBH's ROE is +0.10%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, PBH is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check ZYXI's competition here
PBH vs SNYR Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, SNYR has a market cap of 2.8M. Regarding current trading prices, PBH is priced at $46.75, while SNYR trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas SNYR's P/E ratio is -0.23. In terms of profitability, PBH's ROE is +0.10%, compared to SNYR's ROE of +1.01%. Regarding short-term risk, PBH is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check SNYR's competition here
PBH vs MEHA Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, MEHA has a market cap of 590.9K. Regarding current trading prices, PBH is priced at $46.75, while MEHA trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas MEHA's P/E ratio is 8.58. In terms of profitability, PBH's ROE is +0.10%, compared to MEHA's ROE of +1.19%. Regarding short-term risk, PBH is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check MEHA's competition here
PBH vs RDGT Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, RDGT has a market cap of 351. Regarding current trading prices, PBH is priced at $46.75, while RDGT trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas RDGT's P/E ratio is -0.02. In terms of profitability, PBH's ROE is +0.10%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, PBH is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check RDGT's competition here
PBH vs CVET Comparison May 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.2B. In comparison, CVET has a market cap of 0. Regarding current trading prices, PBH is priced at $46.75, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 11.94, whereas CVET's P/E ratio is -69.97. In terms of profitability, PBH's ROE is +0.10%, compared to CVET's ROE of -0.06%. Regarding short-term risk, PBH is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check CVET's competition here